SMS Pharmaceuticals Q2 FY27: Consolidated revenue Rs 316.09 cr, PAT Rs 39.85 cr
Results$SMSPHARMA

SMS Pharmaceuticals Q2 FY27: Consolidated revenue Rs 316.09 cr, PAT Rs 39.85 cr

For Q2 FY27, SMS Pharmaceuticals’ consolidated revenue was Rs 316.09 cr and net profit Rs 39.85 cr, up from Rs 242.43 cr and Rs 25.31 cr a year earlier.

SMS Pharmaceuticals Ltd
SMS Pharmaceuticals LtdReviewed and published by · How we report
3 min read
sms pharmaceuticalsq2 fy27earningspharmaresults
ShareWhatsAppXLinkedIn

Key takeaways

  • Revenue from operations Rs 316.09 cr vs Rs 242.43 cr a year earlier
  • Total income Rs 317.43 cr vs Rs 243.86 cr in the quarter ended 30/09/2025
  • Total expenses Rs 264.61 cr vs Rs 209.82 cr in the corresponding quarter
  • Net profit after taxes and associate share Rs 39.85 cr vs Rs 25.31 cr
  • Earnings per share Rs 4.26 vs Rs 2.84 in the corresponding quarter of the previous year

Q2 FY27 · consolidated

MetricSep 2026Sep 2025Change
RevenueRs 316.09 crRs 242.43 cr+30.4%
PATRs 39.85 crRs 25.31 cr+57.5%

As reported in the filing. Figures are transcribed, not computed.

SMS Pharmaceuticals Ltd's next results reach Pro the minute they're filed.Try Pro free for 14 days

What the numbers show

  • Net margin was 12.52% of revenue, up 215 bps from 10.37%.
  • Revenue rose 30.4% while total expenses rose 26.1%.

• Revenue from operations (Q2 FY27, consolidated): Rs 316.09 cr, vs Rs 242.43 cr in the quarter ended 30/09/2025, as per the consolidated statement of unaudited financial results.

• Total income: Rs 317.43 cr, vs Rs 243.86 cr a year earlier.

• Total expenses: Rs 264.61 cr, vs Rs 209.82 cr in the corresponding quarter of the previous year.

• Cost of materials consumed: Rs 168.08 cr, vs Rs 104.99 cr a year ago.

• Changes in inventories: Rs 12.37 cr, vs Rs 33.19 cr in the quarter ended 30/09/2025.

• Employee benefits expense: Rs 27.26 cr, vs Rs 19.25 cr in the year-ago quarter.

• Finance cost: Rs 5.74 cr, vs Rs 5.74 cr a year earlier.

• Depreciation and amortization expense: Rs 10.44 cr, vs Rs 10.02 cr in the corresponding quarter of the previous year.

• Other expenses: Rs 15.93 cr, vs Rs 10.89 cr a year ago.

• Profit before tax (PBT): Rs 52.82 cr, compared with Rs 34.04 cr in the quarter ended 30/09/2025.

• Tax expense (total): Rs 13.25 cr, vs Rs 8.91 cr in the year-ago quarter.

• Net profit after tax (PAT): Rs 39.57 cr, vs Rs 25.13 cr a year earlier.

• Net profit after taxes and share of profit/(loss) from associate: Rs 39.85 cr, compared with Rs 25.31 cr in the quarter ended 30/09/2025.

• Earnings per share (basic/diluted, not annualised): Rs 4.26, vs Rs 2.84 in the corresponding quarter of the previous year.

For the quarter ended 30/09/2026 (Q2 FY27), SMS Pharmaceuticals Limited reported higher consolidated revenue from operations and total income compared with the quarter ended 30/09/2025, according to the consolidated statement of unaudited financial results. Revenue from operations rose to Rs 316.09 cr from Rs 242.43 cr, while total income increased to Rs 317.43 cr from Rs 243.86 cr.

On the cost side, total expenses increased to Rs 264.61 cr from Rs 209.82 cr a year earlier. Within this, cost of materials consumed moved up to Rs 168.08 cr from Rs 104.99 cr, and employee benefits expense increased to Rs 27.26 cr from Rs 19.25 cr. Depreciation and amortization expense was Rs 10.44 cr versus Rs 10.02 cr in the corresponding quarter of the previous year, while finance cost was Rs 5.74 cr compared with Rs 5.74 cr. Other expenses rose to Rs 15.93 cr from Rs 10.89 cr.

With income growing faster than expenses, profit before tax for the quarter ended 30/09/2026 came in at Rs 52.82 cr, up from Rs 34.04 cr in the quarter ended 30/09/2025. After total tax expense of Rs 13.25 cr (vs Rs 8.91 cr a year earlier), net profit after tax stood at Rs 39.57 cr, compared with Rs 25.13 cr. Including the share of profit in associate, net profit after taxes and share of profit/(loss) from associate was Rs 39.85 cr, up from Rs 25.31 cr in the corresponding quarter of the previous year. Earnings per equity share (face value Re.1/- each), basic and diluted and not annualised, were reported at Rs 4.26 versus Rs 2.84 a year ago.

Get SMS Pharmaceuticals Ltd's next results the minute they're filed

Results reach the exchange at all hours, most of them after the market closes. Pro puts the filing in your feed as it is published, with our read of the numbers. A free account sees it an hourback for a day.

  • We'll start you off following SMSPHARMA.
  • 14 days free, no card. After that you keep a free account.

Get every filing that moves a stock

One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.

Cruxal publishes market coverage for information only. Nothing here is investment advice.

SMS Pharma Q2 FY27: Revenue Rs 316.09 cr | Cruxal